LAVA Therapeutics N.V.
LVTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.04 | 0.07 | 0.03 |
| FCF Yield | -76.67% | -97.10% | 3.81% | -30.68% |
| EV / EBITDA | 0.18 | -0.11 | 0.13 | 0.90 |
| Quality | ||||
| ROIC | -44.77% | -47.08% | -27.76% | -28.59% |
| Gross Margin | 100.00% | 48.56% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.78 | 0.96 | -0.13 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -14.83% | 8.16% | 72.97% | – |
| Free Cash Flow Growth | 52.29% | -1,286.75% | 110.36% | -239.93% |
| Safety | ||||
| Net Debt / EBITDA | 1.27 | 0.94 | 3.07 | 3.55 |
| Interest Coverage | -57.66 | -92.03 | -424.85 | -69.78 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -374.44 | 61.25 | 50.08 |